pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)

This medicine is now withdrawn from use in the European Union.


The marketing authorisation for Pumarix has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 17/03/2015

Authorisation details

Product details
Agency product number
Active substance
pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) 
International non-proprietary name (INN) or common name
pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)
Therapeutic area (MeSH)
  • Influenza, Human
  • Immunization
  • Disease Outbreaks
Anatomical therapeutic chemical (ATC) code
Exceptional circumstancesExceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see Pre-authorisation guidance.

Publication details
Marketing-authorisation holder
GlaxoSmithKline Biologicals S.A. 
Date of issue of marketing authorisation valid throughout the European Union
Contact address
GlaxoSmithKline Biologicals S.A.
89, rue de l'Institut
B-1330 Rixensart

Product information

28/02/2014 Pumarix - EMEA/H/C/001212 - P46/0016

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

Prophylaxis of influenza in an officially declared pandemic situation.

Pandemic-influenza vaccine should be used in accordance with official guidance.

Assessment history

Related content

How useful was this page?

Add your rating
2 ratings